"Leaders in government, business, and society all seek to adopt policies that will spur the development of treatments and preventive therapies for COVID-19 that can be delivered as rapidly as possible in an affordable and equitable manner," said Steven D. Pearson, MD, MSc, ICER's President. "One critical issue will be how new treatments will be priced to ensure that this goal can be met. In the exceptional circumstances of the coronavirus pandemic the early decisions made regarding pricing policy will guide further decisions in the coming months that will have enormous consequences for the United States and the rest of the world."
WHITE PAPER: "Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19"
Released today, ICER's new white paper provides a brief overview of approaches to manage the pricing of novel vaccines and treatments in times of public health emergencies. After summarizing the experiences and lessons learned from previous epidemics and the annual flu vaccine, the paper analyzes the potential advantages and disadvantages of six alternative approaches to pricing that policymakers from around the world must now confront:
COLLOQUIUM SERIES: "Pricing in a Pandemic: Options, Debate, a Path Forward"
ICER will also host a three-part colloquium series of 90-minute webinars with policy makers and experts from diverse perspectives to debate alternative pricing policy approaches for current and future treatments for COVID-19:
Additional speakers for all sessions have been invited, and their names will be made public upon their confirmation. If you would like to nominate a specific expert to be considered, please submit your nomination to email@example.com.
The ICER-COVID Models
To further inform public debate around fair pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19, ICER has also developed its ICER-COVID economic models, which comprise both cost-recovery and cost-effectiveness paradigms. Intended to be updated frequently as new data emerge, the ICER-COVID models were first published on May 1 and most recently updated on June 24.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER's reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER's reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER's reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER's website.
To read more Press Release articles, click here.